Anomeric Spirocycles by Solvent Incorporation: Reactions of O-Peracylated (Glyculopyranose and Glyculopyranosyl Bromide)onamide Derivatives with Ketones by Páhi, András et al.
Our reference: CAR 6720 P-authorquery-v11
AUTHOR QUERY FORMrrections to:Journal: CAR Please e-mail or fax your responses and any coE-mail: corrections.essd@elsevier.sps.co.inPDF
ightArticle Number: 6720 Fax: +31 2048 52799
Dear Author,
Please check your proof carefully and mark all corrections at the appropriate place in the proof (e.g., by using on-screen annotation in the
ﬁle) or compile them in a separate list. Note: if you opt to annotate the ﬁle with software other than Adobe Reader then please also highl
the appropriate place in the PDF ﬁle. To ensure fast publication of your paper please return your corrections within 48 hours.For correction or revision of any artwork, please consult http://www.elsevier.com/artworkinstructions.
Any queries or remarks that have arisen during the processing of your manuscript are listed below and highlighted by ﬂags in the proof. Click
on the ‘Q’ link to go to the location in the proof.
Location in
article
Query / Remark: click on the Q link to go
Please insert your reply or correction at the corresponding line in the proof
Q1 Please confirm that given name(s) and surname(s) have been identified correctly.
Q2 Please check the sentence ‘As...tried’ for clarity, and correct if necessary.
Q3 Please check the usage of the term ‘splitted resonances’ in the sentence ‘Proton...3)’, and correct if
necessary.
Q4 Please provide publisher details for Ref. 16.
Q5 Please specify the significance of footnote ‘⁄’ cited in Table 1, as a corresponding footnote text has not
been provided.
Thank you for your assistance.
Please check this box if you have no
corrections to make to the PDF file
Graphical abstract
CAR 6720 No. of Pages 1, Model 5G
13 April 2014pp xxx–xxxAnomeric spirocycles by solvent incorporation: reactions of O-peracylated (glyculopyranose and glyculopyranosyl
bromide)onamide derivatives with ketones
András Páhi, Katalin Czifrák, Katalin E. Kövér, László Somsák *
O
Br
CONH2(AcylO)n
O
(AcylO)n
O
O
O
(AcylO)n
O
O
R1
R2
R1 R
2HN
NHR1 R2
O
(as solvent)
Ag(I) salt
+O
OH
CONH2(AcylO)n
O
(AcylO)n
O
NH
R1 R
2
O
R1 R2
O
(5 equiv or 
as solvent)
H+
major minor
configurations:
D-gluco, D-galacto1Highlights
 Ketone incorporation reactions.  Preparation of glycopyranosylidene-spiro-(4-imino-1,3-dioxolanes).  Preparation of glycopyranosylidene-
spiro-(oxazolidin-4-ones).
Anomeric spirocycles by solvent incorporation: reactions
of O-peracylated (glyculopyranose and glyculopyranosyl bromide)
onamide derivatives with ketones
András Páhi a, Katalin Czifrák a, Katalin E. Kövér b, László Somsák a,⇑
aDepartment of Organic Chemistry, University of Debrecen, POB 20, H-4010 Debrecen, Hungary
10
bDepartment of Inorganic and Analytical Chemistry, University of Debrecen, POB 21, H-4010 Debrecen, Hungary
20
ylat d
osy rs
g O -
ala le
ts y s,
luco -
,2-d n
nds
d.
d
-
f
,
i-
n
y
50 ic
d
60-
l
8
-
-
a
9
a
-
-
70t
-
Q1
Carbohydrate Research xxx (2014) xxx–xxx
Contents lists available at ScienceDirect
Carbohydrate Research
journal homepage: www.elsevier .com/locate /carres
CAR 6720 No. of Pages 11, Model 5G
15 April 2014a r t i c l e i n f o
Article history:
Received 13 March 2014
Received in revised form 31 March 2014
Accepted 1 April 2014
Available online xxxx
Keywords:
Solvent incorporation
Spiro compounds
Anomeric spirocycles
4-Imino-1,3-dioxolanes
Oxazolidin-4-ones
a b s t r a c t
Reactions of O-peracet
(a-D-gluco-heptulopyran
gave the correspondin
1,3-dioxolanes. The D-g
the D-gluco counterpar
O-perbenzoylated a-D-g
D-glucitol-spiro-[10 ,5]-2
protocol. These compou
1. Introduction
Spirocyclic motifs are widespread among natural products an
synthetic compounds, and often exhibit interesting and useful bio
logical activities.1–3 Spirocycles involving the anomeric carbon o
monosaccharide derivatives are also well known, and have been
among others, shown to possess antiparasitic,4 antibacterial, ant
fungal,5 antidiabetic,6 herbicide,7 glycosidase8–10 and glycoge
phosphorylase11 inhibitory activities.
Synthetic strategies to obtain spirocycles were ampl
reviewed,1–3 and ring closure of geminally disubstituted cycl
compounds were highlighted as one of several generally applie
approaches towards various spiro derivatives. Following this
principle for the preparation of anomeric spirocycles the neces-
sary starting compounds can be selected from monosaccharides
homo- or heterobifunctionalized at the anomeric centre.1 The lat-
ter type precursors are represented among others by derivatives of
ulose type sugars utilized, for example, for the syntheses of many
sorts of spironucleosides.12 In this line we reported the transforma-
tions of (glyculopyranosyl bromide)onic acid derivatives13
http://dx.doi.org/10.1016/j.carres.2014.04.003
0008-6215/ 2014 Published by Elsevier Ltd.
⇑ Corresponding author. Tel.: +36 52512900x22348; fax: +36 52512744.
E-mail address: somsak.laszlo@science.unideb.hu (L. Somsák).
1 Strictly speaking these compounds might no more have a ‘real’ anomeric, that is,
an acetal type carbon in many cases, however, for the sake of simplicity this term will
be used here.
Please cite this article in press as: Páhi, A.; et al. Carbohydr. Res. (20ed (a-D-galacto-heptulopyranosyl bromide)onamide and O-perbenzoylate
l bromide)onamide with ketones in the presence of silver(I) salt promote
-peracylated 10,50-anhydro-D-glycitol-spiro-[10,5]-4-imino-2,2-disubstituted
cto conﬁgured starting compounds furnished both spiro epimers, whi
ielded only conﬁgurationally inverted products. Under acidic condition
-heptulopyranosonamide and ketones yielded the protected 10,50-anhydro
isubstituted-oxazolidin-4-ones, which were O-debenzoylated by the Zemplé
had no inhibition against rabbit muscle glycogen phosphorlyase b.
 2014 Published by Elsevier Lt
to glycopyranosylidene-spiro-(thio)hydantoins,14,15 -thiazolidinon
es,16 and -oxazolines,17 as well as that of (glyculopyranosy
thiocyanate)ononitriles to glycopyranosylidene-spiro-thiazolines.1
Some years ago we observed that on generation of the corre
sponding glycosylium ion from (glyculopyranosyl bromide)ona
mides (e.g., 1) by Ag2CO3 in acetone spiro-imino-dioxolanes 2
and 3a (Table 1) were formed by incorporation of the solvent.1
This reaction can be regarded as a direct O-glycosylation of
ketone which is a very rare transformation: formation of acetal gly
cosides in the presence of ketones was described from O-peracety
lated N-(2,4-dinitrophenyl)-a-D-glucosaminyl bromide (but no
from acetobromoglucose),20 TMS-glycosides21,22 and O-perbenzy
23lated 1-thioglycosides. Formal glycosylation of ketones by a spe-
cial intramolecular aglycon delivery was recently reported.24
In this paper full experimental details are reported for the
extension of the above ketone incorporation in reactions of (glycu-
lopyranosyl bromide)onamides. Furthermore, studies on the reac-
tions of (glyculopyranose)onamides and ketones as well as
detailed structural elucidation of the compounds are also
described.
802. Results and discussion
Following the ﬁrst observation19 on incorporation of acetone
into the products in the reaction of 1 (Table 1, entry 1) in the pres-
ence of Ag2CO3, the applicability of other ketones and promoters
14), http://dx.doi.org/10.1016/j.carres.2014.04.003
were investigated. With butanone both Ag2CO3 and AgOTf gave
similar results (entries 2 and 3) expectedly furnishing the spiro-
dioxolanes 2b and 3b as inseparable diastereomeric mixtures.
Symmetrical ketones (entries 4–6) also gave the spiro-epimers
2c–e as the main products whereby 3c–e could be isolated in much
lower yields. From each reaction mixture the hydrolytic product 4
90 could be isolated in 25–38% yields.
Similar reactions of the D-gluco conﬁgured 5 are collected in
Table 2. Comparisons of entries 1, 3 and 5 with entries 2, 4 and
6, respectively, show that the use of AgOTf is superior to that of
Ag2CO3 in terms of reaction times, although the higher efﬁciency
of the former is not always reﬂected in the yields. In these reac-
tions of 5 only spiro-epimer 6 was observed in the reaction mix-
tures (besides the hydrolyis product 7).
Attempts to reduce the amount of the ketones to 5–10 equiv in
nitromethane as the solvent proved unsuccesful, and the only
100 products to be observed were 4 and 7. Trials to use aldehydes as
the carbonyl reagents resulted in multicomponent mixtures from
which no discrete products could be isolated.
Reactions of (D-gluco-hept-2-ulopyranose)onamide 7 with ke-
tones were investigated next (Table 3). As in similar cyclizations
of non-carbohydrate a-hydroxy-carboxamides p-toluenesulfonic
acid (pTSA) was frequently applied to promote the transforma-
tion25 this acid was tried ﬁrst. However, no reaction of 7 could
be
ca
110 ca
in
8a (entry 2). Under the same conditions butanone gave an insepa-
rable diastereomeric mixture of 8b (entry 3). The amount of the ke-
tone could be diminished to 5 equiv, and both THF and toluene
proved suitable solvents to prepare 8c–f in good yields (entries
4–7). In these reactions formation of one compound was observed
in each case (disregarding diasteromers 8b). Reactions with alde-
hydes gave only decomposition products.
Spiro-oxazolidinones 8 were O-debenzoylated by the Zempén
120protocol to give compounds 9 in very good yields. These deriva-
tives were tested as possible inhibitors of rabbit muscle glycogen
phosphorylase b, however, showed no inhibition up to 625 lM
concentration.
Structural elucidation of the products (following the mass spec-
trometric determination of the molecular masses) was carried out
by NMR methods as illustrated for the compounds depicted in
Figure 1 (see also Table 4 for selected NMR data of the compounds).
Proton spectra showed splitted resonances for a pyranoid ring in
the 4C1 conformation as well as the expected signals of the ali-
130phatic parts and the presence of an exchangable proton assigned
as an NH for each compound (see details in Section 3). The carbon
spectra contained (besides the expected resonances for the sugar
ring, the acyl protecting groups and the aliphatic moieties) signals
for three carbons with no attached hydrogens. Those in the range
of 99.9–100.7 ppm were assigned as the C-[10,5] spiro centres.
Re
fro
of
an
Table 1
Reaction of O-peracetylated (a-D-galacto-heptulopyranosyl bromide)onamide (1) with ketones
 
O
AcO
AcO
AcO OAc
Br
CO
1 2 3 4
NH2
O
AcO
AcO
AcO OAc
O
O
O
AcO
AcO
AcO OAc
O O
O
AcO
AcO
AcO OAc
OH
CONH2
HN
NH
R1
R2
R1 R2
R1 R2
O
as solvent
promoter + +
(1 equiv.)
in the dark, under Ar
rt
Entry R1 R2 Promoter R. time (d) Yield (%)
1 aa Me Me Ag2CO3 1 71 4 5
2 b Me Et Ag2CO3 6 49b c c
3 AgOTf 6 43b 19⁄ 38
4 c Et Et AgOTf 3 32 14 27
5 d –(CH2)4– AgOTf 6 48 Traces 26
6 e –(CH2)5– AgOTf 2 44 8 25
a From Ref. 19.
b Two diastereomers.
c Observed but not isolated.
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Plobserved with acetone as the solvent in the presence of either
talytic or stoichiometric amounts of pTSA. On the other hand,
talytic triﬂic acid (TfOH) elicited the reaction (entry 1), and rais-
g its amount to one equivalent signiﬁcantly increased the yield of
le 2
ction of O-perbenzoylated (a-D-gluco-heptulopyranosyl bromide)onamide (5) with ke
O
BzO
BzO
BzO
OBz
Br
CONH2
R1 R2
O
as solvent
1 equiv. promoter
in the dark, under Ar
rt
B
Bz
5
Entry R1 R2
1 a Me Me
2
3 c Et Et
4
5 d –(CH2)4–
6 e –(CH2)5–ease cite this article in press as: Páhi, A.; et al. Carbohydr. Res. (2014), hsonances of 112.5–122.2 and 158.2–160.9 ppm (clearly distinct
m the C@O resonances of the protective groups) were indicative
acetal and imidate type carbons, respectively, in compounds 2, 3
d 6. On the contrary, the spectra of compounds 8 exhibited
s
O
BzO
OBz
O
O
HN
R1
R2
O
BzO
BzO
BzO
OBz
OH
CONH2+
6 7
moter R. time (d) Yield (%)
CO3 11 17 41
Tf 1 37 46
CO3 20 5 34
Tf 1 46 35
CO3 13 56 18
Tf 1 28 35ttp://dx.doi.org/10.1016/j.carres.2014.04.003
140 an additional signal in the range of the benzoyl carbonyls (162.4–
166.6 ppm) and from these that of the highest chemical shift was
(tentatively) assigned to amide C-4. A resonance in the range of
n
i-
t-
–
s
-
,
150 -
4
e
-
f
s
e
160of the sugar ring. Although these couplings could not be measured
for each compound due to insufﬁcient sample quantities, no doubt
was left about the spiro conﬁguration of the other members of the
s
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166.4
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* ***
*
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*Cross peaks with NH in the spectra from CPMG-HSQMBC experiments.
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Figure 1. Representative NMR data for the structural elucidation of the new compounds.
Table 3
Reaction of 3,4,5,7-tetra-O-benzoyl-a-D-gluco-heptulopyranosonamide (5) with ketones
O
BzO
BzO
BzO
OBz
OH
CONH2 R
1 R2
O
O
BzO
BzO
BzO
OBz
O NH
/ TfOH
solvent, reflux
overnight
O
R2R1
O
HO
HO
HO
OH
O NH
O
R2R1
NaOMe
MeOH, rt
7 8 9
Entry R1 R2 Ketone (equiv.) Solvent Acid (equiv.) Yield (%)
1 a Me Me As solvent — 0.1 58 94
2 As solvent — 1.0 89
3 b Me Et As solvent — 1.0 92a 96
4 c Et Et 5 THF 1.0 69 91
5 d –(CH2)4– 5 THF 1.0 86 91
6 e –(CH2)5– 5 Toluene 1.0 69 96
7 f –(CH2)6– 5 Toluene 1.0 71 77
a Two diastereomers.
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15 April 201492.4–100.1 ppm could be attributed to an aminal type carbo
and this corroborated that the nitrogen was in an endocyclic pos
tion in 8. To conﬁrm the difference in the constitution of the he
erocyclic parts of the spirocycles, CMPG-HSQMBC experiments26
28 were carried out with 6a and 8e. In these spectra cross peak
(indicated by asterisks in the formulae of the respective com
pounds in Fig. 1) between NH and C-4 and C-5, but not with C-2
were observed for 6a to further prove the imino-dioxolane struc
ture. On the other hand, cross peaks between NH and C-2, C-
and C-5, as well as with carbons of the aliphatic substituent wer
present for 8e to verify the oxazolidinone ring. For 8e this mea
surement also corroborated the chemical shift assignment o
amide C-4. The conﬁguration of the spiro carbons C-[10,5] wa
established as R for 2 and 6, and S for 3 and 8 based on the thre
bond heteronuclear coupling constants between H-2 and C-4
shown in Figure 1 indicating the trans diaxial versus gauche rela-
tionships between the respective nuclei in the 4C1 conformation
,
-
,
Please cite this article in press as: Páhi, A.; et al. Carbohydr. Res. (20series. Namely, the proton resonances had characteristic shift
depending on the C-[10,5] conﬁguration (cf. Fig. 1 and Table 4)
H-20 had a downﬁeld shift of 0.1–0.2 ppm if the C@NH/C@
was on the same side of the pyranoid ring; similarly, downﬁel
shifts were observed for H-30 (0.7 ppm) and H-50 (0.4 ppm
when they were in the same situation. Analogous 1H chemical shi
patterns were observed earlier for other glycopyranosylidene
spiro-heterocycles.14,15
Formation of spirocycles 2, 3 and 6 can be understood b
following the mechanistic proposal in Scheme 1. The silver sa
promoter facilitates the generation of the corresponding glycosyl
umion B1 from 1 or 5. Nucleophilic attack of a ketone with anch
meric assistance of the 2-O-acyl group (D1) may lead t
carbocation A1 while without neighbouring group participatio
the epimeric cation, represented by resonance forms E1 and F1
can be formed. Intramolecular attack of the amide oxygen (illus
trated in details for F1 only), the harder part of this functional group14), http://dx.doi.org/10.1016/j.carres.2014.04.003
180 may give the cyclized iminium ion C1. Deprotonation of this inter-
mediate and that of the analogous one (not shown) derived from
A1 give then the isolated products of retained (3) and inverted con-
ﬁguration (2), respectively. Formation of the by-products 4 and 7
are to be explained by the water content of the solvents attacking
on glycosyliumion B1. The ﬁnding that from the D-gluco conﬁgured
5 only the formation of 6was observed,2 while 1 of the D-galacto con-
ﬁguration gave both epimers 2 and 3, may be indicative of a remote
participation29 of the axial 4-O-acetyl group of 1 facilitating the for-
mation of 3.
190
(S
er
alt
tempting) possibility is the protonation of the glycosidic OH in 7
followed by loss of water to give glycosyliumion C2 which is the
same intermediate as B1 in Scheme 1. Attack of a ketone on C2
would give A2 (equal to intermediate F1 in Scheme 1), however,
the formation of the epimeric intermediateA1 (shown in Scheme 1)
must also be taken into account. This possibility renders this path-
200way less probable since only the conﬁgurationally retained epimer
8 was observed in the reactions. Formation of A2 (without epimer-
ization) should also be possible via protonation and subsequent
dehydration of a mixed hemiketal E2 which can develop from 7
by
pr
nu
Sc
th
2)
210tw
Table 4
Selected NMR data for the O-peracylated compoundsa 2, 3, 6 and 8 (d [ppm], J [Hz])
O
AcO
AcO
AcO OAc
O
O
HN
R1
R2
1'2'
3'
4' 5'
2
4
5 2a
b 2b 2c 2d 2e
H-20 5.58 5.54/5.59 5.60 5.57 5.57
H-30 6.00 6.05/5.89 5.99 5.98 6.01
H-50 4.88 4.75/4.85 4.85 4.84 4.85
C-[10 ,5] 100.4 100.2/100.3 99.9 100.1 100.1
C-2 112.6 114.7/114.1 116.8 116.2 113.2
C-4 160.9 160.4/160.2 160.4 158.8 158.2
3JH-20 ,C-4 5.6 4.1 6.1 6.1 5.3
O
AcO
AcO
AcO OAc
O O
NH
R1 R2
1'2'
3'
4' 5'
2
4
5 3ab 3b 3c 3e
H-20 5.74 5.74/5.69 5.74 5.75
H-30 5.25 5.35/5.20 5.30 5.26
H-50 4.41 4.43/4.39 4.42 4.41
C-[10 ,5] 100.3 100.9/100.9 100.8 100.8
C-2 112.5 114.8/113.8 116.2 113.1
C-4 161.2 160.2/160.2 160.8 160.3
3JH-20 ,C-4 n.m.c n.m.c 2.1 n.m.c
O
BzO
BzO
BzO
OBz
O
O
HN
R1
R2
1'2'
3'
4' 5'
2
4
5 6a 6c 6d 6e
H-20 5.85 5.92 5.87 5.87
H-30 6.80 6.82 6.82 6.82
H-50 5.13 5.13 5.12 5.14
C-[10 ,5] 100.3 99.9 99.9 99.8
C-2 112.8 116.6 122.2 113.5
C-4 160.5 160.6 160.3 160.4
3JH-20 ,C-4 5.4 4.9 4.9 5.0
O
BzO
BzO
BzO
OBz
O NH
O
R2R1
1'2'
3'
4' 5'
2
5
4
8a 8b 8c 8d 8e 8f
H-20 5.96 5.99/5.97 6.00 5.97 6.00 5.98
H-30 6.09 6.10/6.09 6.10 6.08 6.10 6.08
H-50 4.66 4.63/4.63 4.64 4.63 4.69 4.66
H-40 5.73 5.72/5.71 5.70 5.73 5.71 5.70
C-[10 ,5] 100.5 100.3/100.35 100.2 100.7 100.1 100.1
C-2 92.4 94.9, 94.5 97.1 100.1 93.5 97.2
C-4 166.0 166.4/166.1 166.6 166.1 166.4 166.1
3JH-20 ,C-4 n.m.c n.m c n.m c n.m.c 2.5 n.m.c
a For substituents R1 and R2 see the respective tables (Table 1 for 2 and 3, Table 2 for 6, and Table 3 for 8).
b Data taken from Ref. 19.
c Not measured because of insufﬁcient sample quantity.
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PlA mechanistic proposal for the formation of spirocycles 8
cheme 2) can be more complex since, due to the presence of sev-
al functional groups whose protonation may start the reaction,
ernative pathways may occur simultaneously. The ﬁrst (most
It is to be noted that from the acetylated counterpart of 5 formation of a very
nor amount (6%) of the inverted product was reported.19ease cite this article in press as: Páhi, A.; et al. Carbohydr. Res. (2014), hnucleophilic addition of the glycosidic OH to the ketone or its
otonated form D2. Ring closure of A2 (=F1) occurred by the
cleophilic attack of the amide oxygen under conditions of
heme 1 (cf. F1?C1) to give the imino-dioxolanes 3, however,
ese compounds were not present in the reactions of 7 (Scheme
. Considering the different reaction conditions this may raise
o possibilities: (i) imino-dioxolanes may be formed as primaryttp://dx.doi.org/10.1016/j.carres.2014.04.003
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15 April 2014products which then give oxazolidinones 8 in a proton catalyse
equilibration; (ii) ring closure takes place by a N-nucleophilic a
tack of the hydroximide tautomer of the amide moiety. The ﬁrs
possibility was ruled out by an experiment in which an imino
dioxolane 6 was subjected to the conditions of the formation o
8. Thus, 6a was boiled in acetone in the presence of TfOH (1 equiv
O
RCO
O
O
RCO
O
O
RCO
O
O
CONH2O
O
R
O
CONH2
RCO
O
A1
D1
Ag
R1
R2
R1
O
R2
R1
O
O
ROCO
O
O
HN
R1
R2
R1 R2
O
Ag /
12 or 6
Scheme 1. Proposed mechanism for the formation of 10 ,5
O
CONH2RCO
O
C2 (= B1 in
Scheme 1)
O CONH2
OHRCO
O
H
R1 R2
O
O
OHRCO
O
OH
NH2
O
OHRCO
O
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O
O
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I2 J2
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RCO
OG2
+
H
-H2O R
1 R2
OH
-H
R1 R2
O
H
-H2
O
RCO
O
OH
NH
A2 (= F1 in
Scheme 1,
cf A1 also)
O
R1 R2
D2
Scheme 2. Possible mechanistic pathways for the formPlease cite this article in press as: Páhi, A.; et al. Carbohydr. Res. (20for 24 h, however, no change could be detected by TLC. The secon
possibility can be reasonable since tautomerization of amides un
der acidic conditions (cf. 7?F2?I2) is a known phenomenon.3
Thus, A2 may ring-close to protonated hydroxy-oxazoline B
which, after deprotonation and tautomerization can give th
isolated 8.
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PlSince a-hydroxy-carboxamides and carbonyl compounds are
own to furnish oxazoles under acidic conditions, the generally ac-
ptedmechanism of the Fischer oxazole synthesis25 should also be
nsidered in the present transformation. Protonation of the amide
ygen of 7 as shown in F2may result in a tautomerization30 to give
least a minor proportion of I2which can attack the ketone (or its
otonated formD2) as aN-nucleophile to give intermediate J2. Pro-
nationof ahydroxyl group in J2may lead to eliminationofwater to
oduce either carbocation G2 orK2, both of which can ring close to
by the nucleophilic attack of the remaining OH on the positively
arged carbon. Due to the presence of three electron releasing sub-
tuents, carbocationK2might bemore stable than glycosyliumion
, therefore, formation ofH2 viaK2might be preferred. This is also
ade likely by the formation of a single isomer of8 thatwould prob-
ly not be the case in route J2?G2?H2. Final deprotonation and
utomerization of H2may then yield the isolable product 8.
Inconclusion, the reactionsof (glyculopyranoseandglyculopyrano-
l bromide)onamides with ketones gave access to the preparation of
w anomeric spirocycles, namely, 10,50-anhydro-D-glycitol-
iro-[10,5]-4-imino-2,2-disubstituted-dioxolanes and 10,50-anhydro-
glycitol-spiro-[10,5]-2,2-disubstituted-oxazolidin-4-ones. The
uctures were unambiguously assigned by NMR methods. Detailed
echanismswere proposed to explain the formation of both constitu-
nal isomers as well as the stereoselectivities of the ring forming
ctions. The spiro-oxazolidinones were tested against rabbit muscle
cogen phosphorlyase b, however, had no inhibitory effect.
Experimental
. General methods
Melting points were measured in open capillary tubes or on a
ﬂer hot-stage and are uncorrected. Optical rotations were deter-
ined with a Perkin–Elmer 241 polarimeter at room temperature.
R spectra were recorded with Bruker 200 (200:50 MHz for
/13C), Bruker DRX 360 (360:90 MHz for 1H/13C) or Avance II
0 (500:125 MHz for 1H/13C) spectrometers. Chemical shifts are
ferenced to Me4Si (1H), or to the solvent signals or DSS in D2O
C). Mass spectra were recorded by a Bruker micrOTOF-Q instru-
ent. TLC was performed on DC-Alurolle Kieselgel 60 F254 (Merck),
d the plates were visualized under UV light and by gentle heat-
g. For column chromatography Kieselgel 60 (Merck, particle size
63–0.200 mm) was used. Dichloromethane was distilled from
O10 and acetone from CaSO4) and stored over 4 Å molecular
ves. Organic solutions were dried over anhydrous MgSO4 and
ncentrated under diminished pressure at 40–50 C (water bath).
. General procedure I for the preparation of O-peracylated
50-anhydro-D-glycitol-spiro-[10,5]-4-imino-2,2-disubstituted-
-dioxolanes 2, 3 and 6
To a solution of an O-peracylated (glyculopyranosyl bro-
ide)onamide 131 or 532 (0.50 g) in a dry ketone (5 mL) containing
olecular sieves (3 Å) Ag2CO3 (1 equiv) or AgOTf/Et3N (1 equiv)
s added. Themixture was stirred at rt in the dark under Ar atmo-
here until TLC (1:1 or 1:2 EtOAc–hexane) showed complete trans-
rmationof the startingmaterial. Then themixturewasﬁlteredona
lite pad and the solvent removed under diminished pressure. The
de product was puriﬁed by column chromatography.
.1. (10R,2RS)- and (10S,2RS)-20,30,40,60-tetra-O-acetyl-10,50-
hydro-D-galactitol-spiro-[10,5]-2-ethyl-4-imino-2-methyl-
-dioxolanes (2b and 3b)
Prepared from 1 (0.50 g, 1.10 mmol) and butanone in the
esence of AgOTf according to General procedure I (Section 3.2).
lumn chromatography (1:1 EtOAc–hexane) gave three fractions.ease cite this article in press as: Páhi, A.; et al. Carbohydr. Res. (2014), hFraction I: 0.21 g (43%) of an inseparable diastereomeric mixture
2b as a colourless oil; Rf = 0.71 (1:1 EtOAc–hexane).
Characterization of diastereomer A: 1H NMR (CDCl3, 360 MHz):
(ppm) 7.40 (s, 1H, NH), 6.05 (dd, 1H, J20 ,30 11.1 Hz, J30 ,40 3.2 Hz,
30), 5.54 (d, 1H, J20 ,30 11.1 Hz, H-20), 5.51 (dd, 1H, J30 ,40 3.2 Hz,
,50 1.0 Hz, H-40), 4.75 (ddd, 1H, J50 ,60a 6.8 Hz, J50 ,60b 6.3 Hz, J40 ,50
Hz, H-50), 4.20–4.02 (m, 2H, H-60a, H-60b), 2.15, 2.05, 1.95,
3 (4s, 12H, OCOCH3), 1.70 (q, 2H, J 7.3 Hz, CH2CH3), 1.35 (s,
, CH3), 0.88 (t, 3H, J 7.3 Hz, CH2CH3); 13C NMR (CDCl3,
MHz): d (ppm) 170.3, 170.0, 169.6, 169.3 (CO), 160.4 (C-4, 3JH-
-4 = 4.1 Hz), 114.7 (C-2), 100.2 (C-10), 69.8, 68.8, 67.5, 66.9 (C-
C-50), 61.3 (C-60), 33.4 (CH2CH3), 25.6 (CH3), 20.7, 20.5, 20.3,
.2 (COCH3); 6.9 (CH2CH3).
Characterization of diastereomer B: 1H NMR (CDCl3, 360 MHz):
(ppm) 7.40 (s, 1H, NH), 5.89 (dd, 1H, J20 ,30 11.1 Hz, J30 ,40 3.2 Hz,
30), 5.59 (1H, d, J20 ,30 11.1 Hz, H-20), 5.48 (dd, 1H, J30 ,40 3.2 Hz,
,50 1.0 Hz, H-40), 4.85 (ddd, 1H, J50 ,60a 6.8 Hz, J50 ,60b 6.3 Hz, J40 ,50
Hz, H-50), 4.20–4.02 (m, 2H, H-60a, H-60b), 2.16, 2.04, 1.98,
4 (4s, 12H, OCOCH3), 1.85 (q, 2H, J 7.3 Hz, CH2CH3), 1.55 (s,
, CH3), 0.96 (t, 3H, J 7.3 Hz, CH2CH3); 13C NMR (CDCl3,
MHz): d (ppm) 170.2, 170.0, 169.8, 169.1 (CO), 160.2 (C-4),
4.1 (C-2), 100.3 (C-10), 69.9, 68.8, 67.2 (2) (C-20–C-50), 61.3 (C-
, 32.4 (CH2CH3), 25.6 (CH3), 20.8, 20.5, 20.3, 20.1 (OCOCH3), 6.9
H2CH3). Calcd for C19H27NO11 (Mol. Wt.: 445.42, Ex. Mass.:
5.16); ESI-MS (positive mode) m/z: 468.148 [M+Na]+, 913.305
M+Na]+.
Fraction II: 0.10 g (19%) of an inseparable diastereomeric mix-
re of 3b as a yellowish oil; Rf = 0.36 (1:1 EtOAc–hexane).
Characterization of diastereomer C: 1H NMR (CDCl3, 360 MHz):
ppm) 7.48 (s, 1H, NH), 5.74 (d, 1H, J20 ,30 11.1 Hz, H-20), 5.51 (dd,
, J30 ,40 3.2 Hz, J40 ,50 1.0 Hz, H-40), 5.35 (dd, 1H, J20 ,30 11.1 Hz, J30 ,40
Hz, H-30), 4.43 (ddd, 1H, J50 ,60a 6.8, J50 ,60b 6.3 Hz, J40 ,50 1.0 Hz,
50), 4.20–4.03 (m, 2H, H-60a, H-60b), 2.10, 2.08, 2.01, 1.98 (4s,
H, OCOCH3), 1.88 (q, 2H, J 7.3 Hz, CH2CH3), 1.54 (s, 3H, CH3),
0 (t, 3H, J 7.3 Hz, CH2CH3); 13C NMR (CDCl3, 90 MHz): d (ppm)
0.4, 170.2, 169.8, 169.1 (CO), 160.2 (C-4), 114.8 (C-2), 100.9
-10), 69.7, 68.6, 67.7, 66.5 (C-20–C-50), 61.7 (C-60), 32.4 (CH2CH3),
.8 (CH3), 20.7, 20.5, 20.2, 20.1 (COCH3); 6.8 (CH2CH3).
Characterization of diastereomer D: 1H NMR (CDCl3, 360 MHz):
ppm) 7.48 (s, 1H, NH), 5.69 (d, 1H, J20 ,30 11.1 Hz, H-20), 5.49 (dd,
, J30 ,40 3.2 Hz, J40 ,50 1.0 Hz, H-40), 5.20 (dd, 1H, J20 ,30 11.1 Hz, J30 ,40
Hz, H-30), 4.39 (ddd, 1H, J50 ,60a 6.8 Hz, J50 ,60b 6.3 Hz, J40 ,50 1.0 Hz,
50), 4.18–4.02 (m, 2H, H-60a, H-60b), 2.11, 2.09, 1.99, 1.97 (4s,
H, OCOCH3), 1.86 (2H, q, J 7.3 Hz, CH2CH3), 1.61 (s, 3H, CH3),
6 (t, 3H, J 7.3 Hz, CH2CH3); 13C NMR (CDCl3, 90 MHz) d (ppm):
0.4, 170.0, 169.9, 169.6 (CO), 160.2 (C-4), 113.8 (C-2), 100.9
-10), 69.7, 67.6, 66.2 (2) (C-20–C-50), 60.3 (C-60), 33.5 (CH2CH3),
.2 (CH3), 20.7, 20.6, 20.2, 20.1 (COCH3); 7.9 (CH2CH3). Calcd for
9H27NO11 (Mol. Wt.: 445.42, Ex. Mass.: 445.16); ESI-MS (positive
ode) m/z: 468.147 [M+Na]+, 913.304 [2M+Na]+.
Fraction III: 0.16 g (38%) of 414 as a white solid.
.2. (10R)- and (10S)-20,30,40,60-tetra-O-acetyl-10,50-anhydro-D-
lactitol-spiro-[10,5]-2,2-diethyl-4-imino-1,3-dioxolanes (2c
d 3c)
Prepared from 1 (0.50 g, 1.10 mmol) and pentan-3-one with
OTf according to General procedure I (Section 3.2). Column chro-
atography (1:1 EtOAc–hexane) gave three fractions.
Fraction I: 0.16 g (32%) of 2c as white crystals; mp: 100–102 C;
]D +37 (c 0.90, CHCl3); 1H NMR (CDCl3, 360 MHz): d (ppm) 7.45
1H, NH), 5.99 (dd, 1H, J20 ,30 11.1 Hz, J30 ,40 3.7 Hz, H-30), 5.60
, 1H, J20 ,30 11.1 Hz, H-20), 5.50 (dd, 1H, J30 ,40 3.7 Hz, J40 ,50 1.2 Hz,
40), 4.85 (ddd, 1H, J50 ,60a 6.8 Hz, J50 ,60b 6.3 Hz, J40 ,50 1.2 Hz, H-50),
7 (dd, 1H, J60a,60b 11.6 Hz, J50 ,60a 6.8 Hz, H-60a), 4.09 (dd, 1H, J60a,60b
.6 Hz, J50 ,60b 6.3 Hz, H-60b), 2.17, 2.06, 2.02, 1.96 (4s, 12H,
OCH3), 1.87 (q, 2H, J 7.3 Hz, CH2CH3), 1.72 (q, 2H, J 7.3 Hz, CH2-ttp://dx.doi.org/10.1016/j.carres.2014.04.003
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13C NMR (CDCl3, 90 MHz): d (ppm) 170.1 (2), 169.6, 169.2 (CO
160.4 (C-4, 3JH-20 ,C-4 = 6.1 Hz from HSQMBC at 125 MHz), 116.
(C-2), 99.9 (C-10), 69.7, 68.9, 67.3 (2) (C-20–C-50), 61.3 (C-60), 31.2
29.4 (CH2CH3), 20.5, 20.4 (2), 20.2 (COCH3); 7.8, 6.7 (CH2CH3).
Fraction II: 0.07 g (14%) of 3c as a white crystals, mp: 61–63 C
[a]D +59 (c 1.00, CHCl3); 1H NMR (CDCl3, 360 MHz): d (ppm) 7.4
(s, 1H, NH), 5.74 (d, 1H, J20 ,30 11.1 Hz, H-20), 5.51 (dd, 1H, J30
3.2 Hz, J40 ,50 1.1 Hz, H-40), 5.30 (dd, 1H, J20 ,30 11.1 Hz, J30 ,40 3.2 H
H-30), 4.42 (ddd, 1H, J50 ,60a 6.8 Hz, J50 ,60b 6.3 Hz, J40 ,50 1.1 Hz, H-50
4.16 (dd, 1H, J60a,60b 11.6 Hz, J50 ,60a 6.8 Hz, H-60a), 4.11 (dd, 1H, J60a,6
11.6 Hz, J50 ,60b 6.3 Hz, H-60b), 2.19, 2.03, 2.01, 1.98 (4s, 12H
OCOCH3), 1.88 (q, 2H, J 7.3 Hz, CH2CH3), 1.84 (q, 2H, J 7.3 H
CH2CH3), 0.99 (t, 3H, J 7.3 Hz, CH2CH3), 0.95 (t, 3H, J 7.3 Hz, CH
CH3); 13C NMR (CDCl3, 90 MHz): d (ppm) 170.3 (2), 170.1, 168.
(CO), 160.8 (C-4, 3JH-20 ,C-4 = 2.1 Hz from HSQMBC at 125 MHz
116.2 (C-2), 100.8 (C-10), 69.6, 69.2, 67.7, 66.1 (C-20–C-50), 61.
(C-60), 31.6, 29.0 (CH2CH3), 20.8, 20.5, 20.3 (2) (COCH3); 8.0, 6.
(CH2CH3); Calcd for C20H29NO11 (Mol. Wt.: 459.44, Ex. Mass
459.17); ESI-MS (positive mode) m/z: 482.163 [M+Na]+, 941.33
[2M+Na]+.
Fraction III: 0.12 g (27%) of 414 as a white solid.
3.2.3. (10R)- and (10S)-20,30,40,60-tetra-O-acetyl-10,50-anhydro-D-
galactitol-spiro-[10,5]-4-imino-1,3-dioxolane-spiro-[2,100]-
cyclopentanes (2d and 3d)
Prepared from 1 (0.20 g, 0.44 mmol) and cyclopentanone wit
AgOTf according to General procedure I (Section 3.2). Column chro
matography (1:1 EtOAc–hexane) gave three fractions.
Fraction I: 0.10 g (48%) of 2d as white crystals; mp: 148–150 C
[a]D +28 (c 0.20, CHCl3); 1H NMR (CDCl3, 360 MHz): d (ppm) 7.40 (
1H, NH), 5.98 (dd, 1H, J20 ,30 11.1 Hz, J30 ,40 3.6 Hz, H-30), 5.57 (d, 1H
J20 ,30 11.1 Hz, H-20), 5.50 (dd, 1H, J30 ,40 3.6 Hz, J40 ,50 1.1 Hz, H-40
4.85 (ddd, 1H, J50 ,60a 6.8 Hz, J5060b 6.3 Hz, J40 ,50 1.1 Hz, H-50), 4.1
(dd, 1H, J60a,60b 11.6 Hz, J50 ,60a 6.8 Hz, H-60a) 4.09 (dd, 1H, J60a,6
11.6 Hz, J50 ,60b 6.3 Hz, H-60b), 2.16, 2.05, 2.03, 1.97 (4s, 12H
OCOCH3), 1.92–1.84 (m, 4H, 2 CH2), 1.82–1.68 (m, 4H, 2 CH2
13C NMR (CDCl3, 90 MHz): d (ppm): 170.0 (2), 169.6, 169.0 (CO
158.8 (C-4, 3JH-20 ,C-4 = 6.1 Hz), 116.2 (C-2), 100.1 (C-10), 69.9
68.6, 67.3, 67.2 (C-20–C-50), 61.2 (C-60), 38.2, 36.6, 23.6, 22.
(4 CH2), 20.6, 20.5 (2), 20.4 (COCH3); Calcd for C20H27NO1
(Mol. Wt.: 457.43, Ex. Mass.: 457.16); ESI-MS (positive mode
m/z: 480.149 [M+Na]+, 937.306 [2M+Na]+.
Fraction II: Traces of 3d insufﬁcient for NMR characterization
Calcd for C20H27NO11 (Mol. Wt.: 457.43, Ex. Mass.: 457.16); ES
MS (positive mode) m/z: 480.147 [M+Na]+, 937.306 [2M+Na]+.
Fraction III: 0.045 g (26%) of 414 as a white solid.
3.2.4. (10R)- and (10S)-20,30,40,60-tetra-O-acetyl-10,50-anhydro-D-
galactitol-spiro-[10,5]-4-imino-1,3-dioxolane-spiro-[2,1]-
cyclohexanes (2e and 3e)
Prepared from 1 (0.50 g, 1.10 mmol) and cyclohexane wit
AgOTf according to General procedure I (Section 3.2). Column chro
matography (1:1 EtOAc–hexane) gave three fractions.
Fraction I: 0.23 g (44%) of 2e as white crystals; mp: 124–126 C
[a]D +14 (c 0.22, CHCl3); 1H NMR (CDCl3, 360 MHz): d (ppm) 7.4
(s, 1H, NH), 6.01 (dd, 1H, J20 ,30 10.5 Hz, J30 ,40 3.2 Hz, H-30), 5.57 (d
1H, J20 ,30 10.5 Hz, H-20), 5.51 (dd, 1H, J30 ,40 3.2 Hz, J40 ,50 1.0 Hz, H-40
4.85 (ddd, 1H, J50 ,60a 7.3 Hz, J50 ,60b 6.3 Hz, J40 ,50 1.0 Hz, H-50
4.10–4.08 (m, 2H, H-60a, H-60b), 2.18, 2.08, 2.04, 1.97 (4s, 12H
OCOCH3), 1.87–1.81 (m, 2H, CH2), 1.77–1.56 (m, 4H, 2 CH2
1.53–1.33 (m, 2H, CH2), 1.30–1.23 (m, 2H, CH2); 13C NMR (CDCl
90 MHz): d (ppm) 170.8 (2), 169.2, 169.8 (CO), 158.2 (C-4, 3JH-20 ,
4 = 5.3 Hz), 113.2 (C-2), 100.1 (C-10), 69.9, 68.9, 67.5 (2) (C-20–C
50), 61.3 (C-60), 37.2, 36.4, 24.4, 23.1 (2) (5 CH2), 20.8, 20.6 (2
20.3 (COCH3); Calcd for C21H29NO11 (Mol. Wt.: 471.46, Ex. MassPlease cite this article in press as: Páhi, A.; et al. Carbohydr. Res. (20471.17); ESI-MS (positive mode) m/z: 494.164 [M+Na]+, 965.33
[2M+Na]+.
Fraction II: 0.04 g (8%) of 3e as white crystals; mp: 112–114 C
[a]D +23 (c 0.20, CHCl3); 1H NMR (CDCl3, 360 MHz): d (ppm) 7.40 (
1H, NH), 5.75 (d, 1H, J20 ,30 10.5 Hz, H-20), 5.50 (dd, 1H, J30 ,40 3.2 H
J40 ,50 1.0 Hz, H-40), 5.26 (dd, 1H, J20 ,30 10.5 Hz, J30 ,40 3.2 Hz, H-30
4.41 (ddd, 1H, J50 ,60a 7.3 Hz, J50 ,60b 6.3 Hz, J40 ,50 1.0 Hz, H-50), 4.1
(dd, 1H, J60a,60b 11.6 Hz, J50 ,60a 7.3 Hz, H-60a), 4.07 (dd, 1H, J60a,6
11.6 Hz, J50 ,60b 6.3 Hz, H-60b), 2.20, 2.06, 2.01, 1.95 (4s, 12H
OCOCH3), 1.88–1.81 (m, 2H, CH2), 1.79–1.60 (m, 6H, 3 CH2
1.52–1.41 (m, 2H, CH2); 13C NMR (CDCl3, 90 MHz): d (ppm) 170.
(2), 168.9, 168.8 (CO), 160.3 (C-4), 113.1 (C-2), 100.8 (C-10), 69.7
69.3, 67.7, 66.0 (C-20–C-50), 61.8 (C-60), 37.0, 36.0, 24.3, 23.3 (2
(5 CH2), 20.6 (2), 20.5 (2) (COCH3); Calcd for C21H29NO11 (Mo
Wt.: 471.46, Ex. Mass.: 471.17); ESI-MS (positive mode) m/z
494.164 [M+Na]+, 965.336 [2M+Na]+.
Fraction III: 0.11 g (25%) of 414 as a white solid.
3.2.5. (10R)-20,30,40,60-Tetra-O-benzoyl-10,50-anhydro-D-glucitol-
spiro-[10,5]-2,2-dimethyl-4-imino-1,3-dioxolane (6a)
Prepared from 5 (0.50 g, 0.71 mmol) and acetone with AgOT
according to General procedure I (Section 3.2). Column chromatog
raphy (1:2 EtOAc–hexane than EtOAc) gave two fractions.
Fraction I: 0.18 g (37%) of 6a as a colourless oil; Rf = 0.51 (1:
EtOAc–hexane); [a]D +63 (c 0.52, CHCl3); 1H NMR (CDCl
360 MHz): d (ppm) 8.04–7.24 (m, 20H, ArH), 7.73 (s, 1H, NH
6.80 (pseudo t, 1H, J20 ,30 10.2 Hz, J30 ,40 9.7 Hz, H-30), 5.85 (d, 1H
J20 ,30 10.2 Hz, H-20), 5.76 (pseudo t, 1H, J40 ,50 9.9 Hz, J30 ,40 9.7 H
H-40), 5.13 (ddd, 1H, J40 ,50 9.9 Hz, J50 ,60b 4.5 Hz, J50 ,60a 1.2 Hz, H-50
4.63 (dd, 1H, J60a,60b 12.0 Hz, J50 ,60a 1.2 Hz, H-60a), 4.47 (dd, 1H, J60a,6
12.0 Hz, J50 ,60b 4.5 Hz, H-60b), 1.61, 1.29 (2s, 6H, CH3); 13C NM
(CDCl3, 90 MHz): d (ppm) 166.0, 165.4, 165.3, 164.8 (CO), 160.
(C-4, 3JH-20 ,C-4 = 5.4 Hz, from HSQMBC at 125 MHz), 112.8 (C-2
100.3 (C-10), 70.8, 70.7, 70.5, 69.4 (C-20–C-50), 63.1 (C-60), 27.6
26.7 (CH3); Calcd for C38H33NO11 (Mol. Wt.: 679.67, Ex. Mass
679.21); ESI-MS (positive mode) m/z: 702.190 [M+Na]+, 1381.39
[2M+Na]+.
Fraction II: 0.21 g (46%) of 732 as a white solid.
3.2.6. (10R)-20,30,40,60-Tetra-O-benzoyl-10,50-anhydro-D-glucitol-
spiro-[10,5]-2,2-diethyl-4-imino-1,3-dioxolane (6c)
Prepared from 5 (0.50 g, 0.71 mmol) and pentan-3-one wit
AgOTf according to General procedure I (Section 3.2). Column chro
matography (1:2 EtOAc–hexane than EtOAc) gave two fractions.
Fraction I: 0.23 g (46%) of 6c as a white foam; Rf = 0.49 (1:
EtOAc–hexane); [a]D +60 (c 0.40, CHCl3); 1H NMR (CDCl
360 MHz): d (ppm) 8.05–7.20 (m, 20H, ArH), 7.71 (s, 1H, NH
6.82 (pseudo t, 1H, J20 ,30 10.2 Hz, J30 ,40 9.8 Hz, H-30), 5.92 (d, 1H
J20 ,30 10.2 Hz, H-20), 5.76 (pseudo t, 1H, J30 ,40 9.8 Hz, J40 ,50 9.7 H
H-40), 5.13 (ddd, 1H, J40 ,50 9.7 Hz, J50 ,60b 5.6 Hz, J50 ,60a 2.2 Hz, H-50
4.64 (dd, 1H, J60a,60b 12.0 Hz, J50 ,60a 2.2 Hz, H-60a), 4.50 (dd, 1H, J60a,6
12.0 Hz, J50 ,60b 5.6 Hz, H-60b), 1.87 (q, 2H, J 7.2 Hz, CH2CH3), 1.57 (q
2H, J 7.4 Hz, CH2CH3), 0.90 (t, 3H, J 7.4 Hz, CH2CH3), 0.63 (t, 3H,
7.4 Hz, CH2CH3); 13C NMR (CDCl3, 90 MHz): d (ppm) 165.9, 165.
(2), 164.8 (CO), 160.6 (C-4, 3JH-20 ,C-4 = 4.9 Hz), 116.6 (C-2), 99.
(C-10), 70.9, 70.7, 70.5, 69.5 (C-20–C-50), 63.0 (C-60), 31.2, 29.1 (CH
CH3), 7.8, 6.6 (CH2CH3); Calcd for C40H37NO11 (Mol. Wt.: 707.72, E
Mass.: 707.24); ESI-MS (positive mode) m/z: 730.223 [M+Na]
1437.468 [2M+Na]+.
Fraction II: 0.16 g (35%) of 732 as a white solid.
3.2.7. (10R)-20,30,40,60-Tetra-O-benzoyl-10,50-anhydro-D-glucitol-
spiro-[10,5]-4-imino-1,3-dioxolane-spiro-[2,100]-cyclopentane
(6d)
Prepared from 5 (0.50 g, 0.71 mmol) and cyclopentanone wit
Ag2CO3 according to General procedure I (Section 3.2). Colum14), http://dx.doi.org/10.1016/j.carres.2014.04.003
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Plromatography (1:2 EtOAc–hexane than EtOAc) gave two
ctions.
Fraction I: 0.28 g (56%) of 6d as a white foam; Rf = 0.55 (1:2
OAc–hexane); [a]D +62 (c 0.46, CHCl3); 1H NMR (CDCl3,
0 MHz): d (ppm) 8.05–7.22 (m, 20H, ArH), 7.75 (s, 1H, NH),
2 (pseudo t, 1H, J20 ,30 10.2 Hz, J30 ,40 9.8 Hz, H-30), 5.87 (d, 1H,
,30 10.2 Hz, H-20), 5.79 (pseudo t, 1H, J40 ,50 9.9 Hz, J30 ,40 9.8 Hz,
40), 5.12 (ddd, 1H, J40 ,50 9.9 Hz, J50 ,60b 4.6 Hz, J50 ,60a 2.8 Hz, H-50),
3 (dd, 1H, J60a,60b 12.1 Hz, J50 ,60a 2.8 Hz, H-60a), 4.49 (dd, 1H, J60a,60b
.1 Hz, J5060b 4.6 Hz, H-60b), 2.15–2.07 (m, 2H, CH2), 1.91–1.86 (m,
, CH2), 1.75–1.54 (m, 4H, 2 CH2); 13C NMR (CDCl3, 90 MHz): d
pm) 165.9, 165.3, 165.2, 164.8 (CO), 160.3 (C-4, 3JH-20 ,C-
4.9 Hz), 122.2 (C-2), 99.9 (C-10), 70.8, 70.6, 70.5, 69.4 (C-20–
50), 62.9 (C-60), 38.0, 36.3, 23.3, 22.4 (4 CH2); Calcd for
0H35NO11 (Mol. Wt.: 705.71, Ex. Mass.: 705.22); ESI-MS (positive
ode) m/z: 728.207 [M+Na]+, 1433.434 [2M+Na]+.
Fraction II: 0.08 g (18%) of 732 as a white solid.
.8. (10R)-20,30,40,60-Tetra-O-benzoyl-10,50-anhydro-D-glucitol-
iro-[10,5]-4-imino-1,3-dioxolane-spiro-[2,100]-cyclohexane
e)
Prepared from 5 (0.50 g, 0.71 mmol) and cyclohexanone with
OTf according to General procedure I (Section 3.2). Column chro-
atography (1:2 EtOAc–hexane than EtOAc) gave two fractions.
Fraction I: 0.14 g (28%) of 6e as a white foam; Rf = 0.61 (1:2
OAc–hexane than EtOAc); [a]D +53 (c 0.40, CHCl3); 1H NMR
DCl3, 360 MHz): d (ppm) 8.04–7.24 (m, 20H, ArH), 7.75 (s, 1H,
), 6.82 (pseudo t, 1H, J20 ,30 10.2 Hz, J30 ,40 9.9 Hz, H-30), 5.87 (d,
, J20 ,30 10.2 Hz, H-20), 5.77 (pseudo t, 1H, J30 ,40 9.9 Hz, J40 ,50 9.7 Hz,
40), 5.14 (ddd, 1H, J40 ,50 9.7 Hz, J50 ,60b 5.0 Hz, J50 ,60a 2.4 Hz, H-50),
1 (dd, 1H, J60a,60b 12.2 Hz, J50 ,60a 2.4 Hz, H-60a), 4.49 (dd, 1H, J60a,60b
.2 Hz, J50 ,60b 5.0 Hz, H-60b), 1.86–1.83 (m, 2H, CH2), 1.55–1.26 (m,
, 4 CH2); 13C NMR (CDCl3, 90 MHz): d (ppm) 165.9, 165.3,
5.2, 164.8 (CO), 160.4 (C-4, 3JH-20 ,C-4 = 5.0 Hz), 113.5 (C-2),
.8 (C-10), 70.7 (2), 70.5, 69.5 (C-20–C-50), 63.0 (C-60), 37.0, 36.0,
.1, 22.9, 22.8 (5 CH2); Calcd for C41H37NO11 (Mol. Wt.:
9.73, Ex. Mass.: 719.24); ESI-MS (positive mode) m/z: 742.224
+Na]+, 1461.462 [2M+Na]+.
Fraction II: 0.16 g (35%) of 732 as a white solid.
. General procedure II for the preparation of O-
rbenzoylated 10,50-anhydro-D-glucitol-spiro-[10,5]-2,2-
substituted-oxazolidin-4-ones 8
Ulosonamide 732 was dissolved in a ketone or in a mixture of
y THF or toluene and 5 equiv of a ketone, then TfOH (1 equiv)
s added. The mixture was stirred at reﬂux temp until TLC (9:1
Cl3–acetone) showed complete transformation of the starting
aterial. Then the mixture was diluted with chloroform, washed
th satd aq NaHCO3, and with water, dried, and the solvent was
aporated. The remaining syrup was puriﬁed by column chroma-
graphy (18:1 CHCl3–acetone).
.1. (10S)-20,30,40,60-Tetra-O-benzoyl-10,50-anhydro-D-glucitol-
iro-[10,5]-2,2-dimethyl-oxazolidin-4-one (8a)
Prepared from 7 (0.1 g, 0.15 mmol) and acetone (5 ml) accord-
g to General procedure II (Section 3.3) to give 0.09 g (89%) of
as a white solid. Mp.: 104–107 C; Rf = 0.74 (9:1 CHCl3–ace-
ne); [a]D +45 (c 0.40, CHCl3); 1H NMR (CDCl3, 360 MHz): d
pm) 8.70 (s, 1H, NH), 7.99–7.20 (m, 20H, ArH), 6.09 (t, 1H, J20 ,30
Hz, J30 ,40 9.8 Hz, H-30), 5.96 (d, 1H, J20 ,30 9.8 Hz, H-20), 5.73 (t,
, J40 ,50 9.8 Hz, J30 ,40 9.8 Hz, H-40), 4.66 (ddd, 1H, J40 ,50 9.8 Hz, J50 ,60b
Hz, J50 ,60a 2.4 Hz, H-50), 4.58 (dd, 1H, J60a,60b 12.3 Hz, J50 ,60a
Hz, H-60a), 4.47 (dd, 1H, J60a,60b 12.3 Hz, J50 ,60b 5.5 Hz, H-60b),
4 (s, 3H, CH3), 1.57 (s, 3H, CH3); 13C NMR (CDCl3, 90 MHz): d
pm) 166.0 (C-4), 165.8, 165.7, 165.1, 164.3 (CO), 133.4–128.1 0.7
ease cite this article in press as: Páhi, A.; et al. Carbohydr. Res. (2014), hrC), 100.5 (C-10), 92.4 (C-2), 71.8, 70.1, 69.4, 68.3 (C-20–C-50),
.2 (C-60), 29.5 (CH3), 28.3 (CH3); Calcd for C38H33NO11 (Mol.
t.: 679.67, Ex. Mass.: 679.21); ESI-MS (positive mode) m/z:
2.192 [M+Na]+, 1381.402 [2M+Na]+.
.2. (10S,2RS)-20,30,40,60-Tetra-O-benzoyl-10,50-anhydro-D-
citol-spiro-[10,5]-2-ethyl-2-methyl-oxazolidin-4-ones (8b)
Prepared from 7 (0.1 g, 0.15 mmol) and butanone (5 ml) accord-
g to General procedure II (Section 3.3) to give 0.1 g (92%) an
separable mixture of 8b as a white solid. Rf = 0.58 (9:1 CHCl3–
etone); [a]D +22 (c 0.42, CHCl3); 1H NMR (CDCl3, 360 MHz): d
pm) 8.89 (s, 1H, NH), 8.05–7.24 (m, 20H, ArH), 6.10, 6.09 (t,
, J20 ,30 10.4 Hz, J30 ,40 9.8 Hz, H-30), 5.99, 5.97 (d, 1H, J20 ,30 10.4 Hz,
20), 5.72, 5.71 (t, 1H, J40 ,50 9.8 Hz, J30 ,40 9.8 Hz, H-40), 4.63 (ddd,
, J40 ,50 9.8 Hz, J50 ,60b 5.5 Hz, J50 ,60a 2.4 Hz, H-50), 4.59 (dd, 1H, J60a,60b
.3 Hz, J50 ,60a 2.4 Hz, H-60a), 4.45 (dd, 1H, J60a,60b 12.3 Hz, J50 ,60b
Hz, H-60b), 1.89, 1.85 (2q, 2H, J 7.5 Hz, CH2), 1.65, 1.56 (2s,
, CH3), 0.98, 0.95 (2t, 3H, J 7.5 Hz CH3); 13C NMR (CDCl3,
MHz): d (ppm) 166.4, 166.1 (C-4), 165.9, 165.6, 165.1, 164.3
O), 133.4–128.1 (ArC), 100.3 (C-10), 94.9, 94.5 (C-2), 71.7, 70.3,
.9, 69.4, 69.3, 68.6, 68.4 (C-20–C-50), 63.2 (C-60), 34.9, 33.7
H2), 27.3, 26.1 (CH3), 8.0, 7.5 (CH3); Calcd for C39H35NO11 (Mol.
t.: 693.70, Ex. Mass.: 693.22); ESI-MS (positive mode) m/z:
6.209 [M+Na]+, 1409.435 [2M+Na]+.
.3. (10S)-20,30,40,60-Tetra-O-benzoyl-10,50-anhydro-D-glucitol-
iro-[10,5]-2,2-diethyl-oxazolidin-4-one (8c)
Prepared from 7 (0.1 g, 0.15 mmol) and pentan-3-one (82 ll,
5 mmol) in dry THF (5 ml) according to General procedure II
ection 3.3) to give 0.07 g (69%) of 8c as a white solid. Mp.:
1–103 C; Rf = 0.66 (9:1 CHCl3–acetone); [a]D +27 (c 0.32,
Cl3); 1H NMR (CDCl3, 360 MHz): d (ppm) 9.07 (s, 1H, NH),
0–7.17 (m, 20H, ArH), 6.10 (t, 1H, J2,030 9.8 Hz, J30 ,40 9.8 Hz, H-
, 6.00 (d, 1H, J20 ,30 9.8 Hz, H-20), 5.70 (t, 1H, J40 ,50 9.8 Hz, J30 ,40
Hz, H-40), 4.64 (ddd, 1H, J40 ,50 9.8 Hz, J50 ,60b 6.7 Hz, J50 ,60a 2.4 Hz,
50), 4.60 (dd, 1H, J60a,60b 12.3 Hz, J50 ,60a 2.4 Hz, H-60a), 4.45 (dd,
, J60a,60b 12.3 Hz, J50 ,60b 6.7 Hz, H-60b), 1.86, 1.75 (2q, 4H, J 7.0 Hz,
2), 0.89, 0.85 (2t, 6H, J 7.0 Hz, CH3); 13C NMR (CDCl3, 90 MHz):
ppm) 166.6 (C-4), 165.9, 165.6, 165.1, 164.3 (CO), 133.4–128.1
rC), 100.2 (C-10), 97.1 (C-2), 71.6, 70.2, 69.4, 68.6 (C-20–C-50),
.3 (C-60), 32.2 (CH2), 30.9 (CH2), 7.8 (CH3), 7.3 (CH3); Calcd for
0H37NO11 (Mol. Wt.: 707.72, Ex. Mass.: 707.24); ESI-MS (positive
ode) m/z: 730.225 [M+Na]+, 1437.464 [2M+Na]+.
.4. (10S)-20,30,40,60-Tetra-O-benzoyl-10,50-anhydro-D-glucitol-
iro-[10,5]-4-oxo-oxazolidine-spiro-[2,100]-cyclopentane (8d)
Prepared from 7 (0.1 g, 0.15 mmol) and cyclopentanone (70 ll,
5 mmol) in dry THF (5 ml) according to General procedure II
ection 3.3) to give 0.08 g (78%) of 8d as a white solid. Mp.: 180–
2 C; Rf = 0.72 (9:1 CHCl3–acetone); [a]D +49 (c 0.62, CHCl3); 1H
R (CDCl3, 360 MHz): d (ppm) 8.84 (s, 1H, NH), 8.04–7.28 (m,
H, ArH), 6.08 (t, 1H, J20 ,30 9.8 Hz, J30 ,40 9.8 Hz, H-30), 5.97 (d, 1H,
,30 9.8 Hz, H-20), 5.73 (t, 1H, J40 ,50 9.2 Hz, J30 ,40 9.8 Hz, H-40), 4.63
dd, 1H, J40 ,50 9.2 Hz, J50 ,60b 6.1 Hz, J50 ,60a 3.1 Hz, H-50), 4.58 (dd, 1H,
a,60b 12.3 Hz, J50 ,60a 3.1 Hz, H-60a), 4.47 (dd, 1H, J60a,60b 12.3 Hz, J50 ,60b
Hz, H-60b), 2.08–1.71 (m, 8H, 4 CH2); 13C NMR (CDCl3,
MHz): d (ppm) 166.1 (C-4), 165.9, 165.7, 165.1, 164.3 (CO),
3.4–128.1 (ArC), 100.7 (C-10), 100.1 (C-2), 71.8, 70.2, 69.4, 68.3
-20–C-50), 63.2 (C-60), 39.9, 37.7, 23.1, 22.6 (CH2); Calcd for
0H35NO11 (Mol. Wt.: 705.71, Ex. Mass.: 705.22); ESI-MS (positive
ode) m/z: 728.210 [M+Na]+, 1433.435 [2M+Na]+.
.5. (10S)-20,30,40,60-Tetra-O-benzoyl-10,50-anhydro-D-glucitol-
iro-[10,5]-4-oxo-oxazolidine-spiro-[2,100]-cyclohexane (8e)
Prepared from 7 (0.1 g, 0.15 mmol) and cyclohexanone (80 ll,
5 mmol) in dry toluene (5 ml) according to General procedure
ttp://dx.doi.org/10.1016/j.carres.2014.04.003
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15 April 2014II (Section 3.3) to give 0.07 g (69%) of 8e as a white solid. Mp.: 178
181 C; Rf = 0.78 (9:1 CHCl3–acetone); [a]D +52 (c 0.46, CHCl3); 1
NMR (CDCl3, 360 MHz): d (ppm) 9.00 (s, 1H, NH), 8.12–7.30 (m
20H, ArH), 6.10 (t, 1H, J20 ,30 9.8 Hz, J30 ,40 9.8 Hz, H-30), 6.00 (d, 1H
J20 ,30 9.8 Hz, H-20), 5.71 (t, 1H, J40 ,50 9.8 Hz, J30 ,40 9.8 Hz, H-40), 4.6
(ddd, 1H, J40 ,50 9.8 Hz, J50 ,60b 6.7 Hz, J50 ,60a 3.1 Hz, H-50), 4.63 (dd, 1H
J60a,60b 12.3 Hz, J50 ,60a 3.1 Hz, H-60a), 4.45 (dd, 1H, J60a,60b 12.3 Hz, J50 ,6
6.7 Hz, H-60b), 1.92–1.32 (m, 10H, 5 CH2); 13C NMR (CDCl
90 MHz): d (ppm) 166.4 (C-4, 3JH-20 ,C-4 = 2.5 Hz from HSQMBC a
125 MHz), 166.0, 165.7, 165.2, 164.3 (C0O), 133.4–128.2 (ArC
100.1 (C-10), 93.5 (C-2), 71.8, 70.3, 69.4, 68.3 (C-20–C-50), 63.3 (C
60), 39.0, 37.6, 24.3, 22.9, 22.6 (CH2); Calcd for C41H37NO11 (Mo
Wt.: 719.73, Ex. Mass.: 719.24); ESI-MS (positive mode) m/
742.222 [M+Na]+, 1462.462 [2M+Na]+.
3.3.6. (10S)-20,30,40,60-Tetra-O-benzoyl-10,50-anhydro-D-glucitol-
spiro-[10,5]-4-oxo-oxazolidine-spiro-[2,100]-cycloheptane (8f)
Prepared from 7 (0.1 g, 0.15 mmol) and cycloheptanone (81 l
0.75 mmol) in dry toluene (5 ml) according to General procedur
II (Section 3.3) to give 0.08 g (71%) of 8f as a white solid. Mp
124–126 C; Rf = 0.55 (9:1 CHCl3–acetone); [a]D +59 (c 0.36
CHCl3); 1H NMR (CDCl3, 360 MHz): d (ppm) 9.31 (s, 1H, NH
0 0 0 08.00–7.18 (m, 20H, ArH), 6.08 (t, 1H, J2 ,3 9.8 Hz, J3 ,4 9.8 Hz, H-
30), 5.98 (d, 1H, J20 ,30 9.8 Hz, H-20), 5.70 (t, 1H, J40 ,50 9.8 Hz, J30 ,40
9.8 Hz, H-40), 4.66 (ddd, 1H, J40 ,50 9.8 Hz, J50 ,60b 6.8 Hz, J50 ,60a 3.1 Hz,
H-50), 4.61 (dd, 1H, J60a,60b 12.3 Hz, J50 ,60a 3.1 Hz, H-60a), 4.44 (dd,
1H, J60a,60b 12.3 Hz, J50 ,60b 6.8 Hz, H-60b), 2.12–1.45 (m, 12H, 6
CH2); 13C NMR (CDCl3, 90 MHz): d (ppm) 166.1 (C-4), 165.9,
165.6, 165.1, 164.2 (CO), 133.3–128.1 (ArC), 100.1 (C-10), 97.2 (C-
2), 71.8, 70.1, 69.4, 68.3 (C-20–C-50), 63.2 (C-60), 42.4, 41.2, 28.2,
28.1, 21.4, 21.1 (CH2); Calcd for C42H39NO11 (Mol. Wt.: 733.76,
Ex. Mass.: 733.25); ESI-MS (positive mode) m/z: 756.240
[M+Na]+, 1490.498 [2M+Na]+.
3.4. General procedure III for the removal of O-acyl protecting
groups
An O-acylated compound was dissolved in the minimum vol-
ume of abs MeOH and a few drops of NaOMe in MeOH (1 M) were
added. The mixture was stirred at rt until TLC (9:1 CHCl3–MeOH)
showed complete transformation of the starting material. It was
then neutralized with a cation exchange resin Amberlyst 15
(H+ form). Filtration and solvent removal left a syrup which was
puriﬁed by column chromatography (CHCl3–MeOH).
3.4.1. (10S)-10,50-Anhydro-D-glucitol-spiro-[10,5]-2,2-dimethyl-
oxazolidin-4-one (9a)
Prepared from 8a (0.14 g, 0.20 mmol) according to General pro-
cedure III (Section 3.4) to give 0.05 g (94%) of 9a as a white solid.
Mp.: 97–99 C; Rf = 0.3 (8:2 CHCl3–MeOH); [a]D +50 (c 0.28,
MeOH); 1H NMR (D2O 360 MHz): d (ppm) 3.90–3.67 (m, 5H, H-20,
H-30 or H-40, H-50, H-60ab), 3.51 (pseudo t, 1H, J = 8.7 Hz, 7.7 Hz,
H-30 or H-40), 1.61 (s, 3H, CH3), 1.58 (s, 3H, CH3); 13 NMR (D2O,
90 MHz): d (ppm) 168.4 (C-4), 102.3 (C-10), 92.6 (C-2), 74.1, 73.6,
69.7, 69.4 (C-20–C-50), 60.6 (C-60), 28.6 (CH3), 27.1 (CH3); Calcd
for C10H17NO7 (Mol. Wt.: 263.24, Ex. Mass.: 263.10); ESI-MS (posi-
tive mode) m/z: 286.088 [M+Na]+, 549.192 [2M+Na]+, 812.290
[3M+Na]+.
3.4.2. (10S,2RS)-10,50-Anhydro-D-glucitol-spiro-[10,5]-2-ethyl-2-
methyl-oxazolidin-4-ones (9b)
Prepared from 8b (0.17 g, 0.25 mmol) according to General pro-
cedure III (Section 3.4) to give 0.06 g (96%) of 9b as a white solid.
Rf = 0.3 (8:2 CHCl3–MeOH); [a]D +53 (c 0.46, MeOH); 1H NMR
Please cite this article in press as: Páhi, A.; et al. Carbohydr. Res. (20(D2O 360 MHz): d (ppm) 3.82–3.44 (m, 6H, H-20, H-30, H-40, H-5
H-60ab), 1.79–1.75 (m, 2H, CH2), 1.51, 1.48 (2s, 3H, CH3), 0.9
0.86 (2t, 3H, J 7.5 Hz CH3); 13C NMR (D2O, 90 MHz): d (ppm
168.9, 168.6 (C-4), 102.2, 101.9 (C-10), 95.2, 94.7 (C-2), 74.3, 73.9
73.5, 69.8, 69.7, 69.5, 69.3 (C-20–C-50), 60.5 (C-60), 34.1, 33.
(CH2), 26.4, 25.3 (CH3), 7.3, 6.9 (CH3); Calcd for: C11H19NO7 (Mo
Wt.: 277.27, Ex. Mass.: 277.12); ESI-MS (positive mode) m/z
300.104 [M+Na]+, 577.225 [2M+Na]+, 854.342 [3M+Na]+.
3.4.3. (10S)-10,50-Anhydro-D-glucitol-spiro-[10,5]-2,2-diethyl-
oxazolidin-4-one (9c)
Prepared from 8c (0.14 g, 0.20 mmol) according to General pro
cedure III (Section 3.4) to give 0.05 g (91%) of 9c as a white solid
Mp.: 70–72 C; Rf = 0.3 (8:2 CHCl3–MeOH); [a]D +48 (c 0.44
MeOH); 1H NMR (D2O 360 MHz): d (ppm) 3.82–3.61 (m, 5H, H-2
H-30 or H-40, H-50, H-60ab), 3.44 (t, 1H, J = 7.6 Hz, 7.6 Hz, H-30 o
H-40) 1.82–1.75 (m, 4H, 2 CH2), 0.89, 0.87 (2t, 6H, J 7.5 Hz, 2
CH3); 13C NMR (D2O, 90 MHz): d (ppm) 168.9 (C-4), 101.9 (C-10
97.3 (C-2), 74.1, 73.5, 69.9, 69.4 (C-20–C-50), 60.5 (C-60), 31.4, 30.
(CH2), 7.1, 6.9 (CH3); Calcd for C12H21NO7 (Mol. Wt.: 291.30, E
Mass.: 291.13); ESI-MS (positive mode) m/z: 314.120 [M+Na]
605.255 [2M+Na]+, 896.387 [3M+Na]+.
3.4.4. (10S)-10,50-Anhydro-D-glucitol-spiro-[10,5]-oxazolidin-4-
680one-spiro-[2,100]-cyclopentane (9d)
Prepared from 8d (0.19 g, 0.27 mmol) according to General pro-
cedure III (Section 3.4) to give 0.07 g (91%) of 9d as a white solid.
Mp.: 112–115 C; Rf = 0.3 (8:2 CHCl3–MeOH); [a]D +46 (c 0.43,
MeOH); 1H NMR (D2O 360 MHz): d (ppm) 3.82–3.62 (m, 5H, H-20,
H-30 or H-40, H-50, H-60ab), 3.44 (pseudo t, 1H, J = 7.8 Hz, 7.3 Hz,
H-30 or H-40) 1.94–1.69 (m, 8H, 4 CH2); 13C NMR (D2O,
90 MHz): d (ppm) 168.6 (C-4), 101.9, 101.8 (C-10, C-2), 74.2, 73.6,
69.6, 69.3 (C-20–C-50), 60.5 (C-60), 39.3, 36.9, 22.8, 22.2 (CH2); Calcd
for C12H19NO7 (Mol. Wt.: 289.28, Ex. Mass.: 289.12); ESI-MS (posi-
690tive mode) m/z: 312.104 [M+Na]+, 601.222 [2M+Na]+, 890.335
[3M+Na]+.
3.4.5. (10S)-10,50-Anhydro-D-glucitol-spiro-[10,5]-oxazolidin-4-
one-spiro-[2,100]-cyclohexane (9e)
Prepared from 8e (0.18 g, 0.25 mmol) according to General pro-
cedure III (Section 3.4) to give 0.07 g (96%) of 9e as a white solid.
Mp.: 123–126 C; Rf = 0.3 (8:2 CHCl3–MeOH); [a]D +42 (c 0.32,
MeOH); 1H NMR (D2O 360 MHz): d (ppm) 3.86–3.62 (m, 5H, H-20,
H-30 or H-40, H-50, H-60ab), 3.48 (pseudo t, 1H, J = 8.9 Hz, 7.9 Hz,
H-30 or H-40) 1.87–1.37 (m, 10H, 5 CH2); 13C NMR (D2O,
70090 MHz): d (ppm) 168.6 (C-4), 101.8 (C-10), 93.6 (C-2), 74.3, 73.6,
69.7, 69.4 (C-20–C-50), 60.6 (C-60), 38.5, 36.6, 23.9, 22.6, 22.2
(CH2); Calcd for C13H21NO7 (Mol. Wt.: 303.31, Ex. Mass.: 303.13);
ESI-MS (positive mode) m/z: 326.120 [M+Na]+, 629.253
[2M+Na]+, 932.384 [3M+Na]+.
3.4.6. (10S)-10,50-Anhydro-D-glucitol-spiro-[10,5]-oxazolidin-4-
one-spiro-[2,100]-cycloheptane (9f)
Prepared from 8f (0.19 g, 0.26 mmol) according to General pro-
cedure III (Section 3.4) to give 0.06 g (77%) of 9f as a white solid.
Mp.: 116–119 C; Rf = 0.3 (8:2 CHCl3–MeOH); [a]D +48 (c 0.30,
710MeOH); 1H NMR (D2O 360 MHz): d (ppm) 3.88–3.67 (m, 5H, H-20,
H-30 or H-40, H-50, H-60ab), 3.50 (pseudo t, 1H, J = 7.4 Hz, 7.2 Hz,
H-30 or H-40) 2.14–1.52 (m, 12H, 6 CH2); 13C NMR (D2O,
90 MHz): d (ppm) 168.4 (C-4), 101.9 (C-10), 97.4 (C-2), 74.2, 73.6,
69.8, 69.4 (C-20–C-50), 60.6 (C-60), 41.8, 40.6, 28.3, 28.2, 21.1, 21.0
(CH2); Calcd for C14H23NO7 (Mol. Wt.: 317.33, Ex. Mass.: 317.15);
ESI-MS (positive mode) m/z: 340.136 [M+Na]+, 657.287
[2M+Na]+, 974.436 [3M+Na]+.
14), http://dx.doi.org/10.1016/j.carres.2014.04.003
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